PE20081168A1 - Agonistas de los anticuerpos de la quinasa trkb y sus usos - Google Patents
Agonistas de los anticuerpos de la quinasa trkb y sus usosInfo
- Publication number
- PE20081168A1 PE20081168A1 PE2007001546A PE2007001546A PE20081168A1 PE 20081168 A1 PE20081168 A1 PE 20081168A1 PE 2007001546 A PE2007001546 A PE 2007001546A PE 2007001546 A PE2007001546 A PE 2007001546A PE 20081168 A1 PE20081168 A1 PE 20081168A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- composing
- antibody agonists
- kinase antibody
- refers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UN ANTICUERPO HUMANIZADO DE CADENA SIMPLE QUE COMPRENDE: A) UNA REGION VARIABLE DE CADENA PESADA QUE COMPRENDE LA SEC ID Nº:5, SEC ID Nº:7, SEC ID Nº:11 Y SEC ID Nº:15; B) UNA REGION VARIABLE DE CADENA LIGERA QUE COMPRENDE LA SEC ID Nº:6, SEC ID Nº:8; SEC ID Nº:12 Y SEC ID Nº:16. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE DICHO ANTICUERPO Y QUE ADEMAS PUEDE CONTENER OTRO AGENTE PARA REDUCIR LA GLUCOSA DE LA SANGRE TAL COMO INSULINA, SULFONIL-UREAS, INHIBIDORES DE LIPASA, LEPTINA, ENTRE OTROS. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE DIABETES, OBESIDAD
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85816906P | 2006-11-09 | 2006-11-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20081168A1 true PE20081168A1 (es) | 2008-09-22 |
Family
ID=39365312
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2007001546A PE20081168A1 (es) | 2006-11-09 | 2007-11-09 | Agonistas de los anticuerpos de la quinasa trkb y sus usos |
Country Status (27)
Country | Link |
---|---|
US (1) | US20100150914A1 (es) |
EP (1) | EP2087007A2 (es) |
JP (1) | JP2010509354A (es) |
KR (1) | KR20090088896A (es) |
CN (1) | CN101573381A (es) |
AR (1) | AR063640A1 (es) |
AU (1) | AU2007316418A1 (es) |
BR (1) | BRPI0719000A2 (es) |
CA (1) | CA2669205A1 (es) |
CL (1) | CL2007003236A1 (es) |
CO (1) | CO6180432A2 (es) |
CR (1) | CR10779A (es) |
DO (1) | DOP2009000102A (es) |
EA (1) | EA200970469A1 (es) |
EC (1) | ECSP099392A (es) |
IL (1) | IL198468A0 (es) |
MA (1) | MA30922B1 (es) |
MX (1) | MX2009004881A (es) |
NI (1) | NI200900081U (es) |
NO (1) | NO20092217L (es) |
PE (1) | PE20081168A1 (es) |
RU (1) | RU2009121641A (es) |
SM (1) | SMAP200900040A (es) |
TN (1) | TN2009000181A1 (es) |
TW (1) | TW200829270A (es) |
WO (1) | WO2008058127A2 (es) |
ZA (1) | ZA200902943B (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA201000603A1 (ru) * | 2007-10-23 | 2010-12-30 | Новартис Аг | ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ |
CL2009000090A1 (es) * | 2008-01-17 | 2009-07-24 | Irm Llc | Anticuerpo que se une al receptor de tirosina quinasa b (trkb); composicion que comprende el anticuerpo; metodo para reducir los niveles de glucosa en la sangre y/o el peso corporal en un individuo. |
EP2408455B1 (en) * | 2009-03-20 | 2014-06-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Inhibitors of cathepsin S for prevention or treatment of obesity-associated disorders |
GB2491106A (en) * | 2011-05-18 | 2012-11-28 | Univ Basel | Antibodies against tropomyosin-related kinase B receptors |
CN104244981A (zh) * | 2011-12-09 | 2014-12-24 | 诺和诺德A/S | Glp-1激动剂 |
CN102944674B (zh) * | 2012-11-05 | 2014-10-22 | 武汉远征世纪制药有限公司 | 一种检测TrkB受体pan-Tyr位点活性的ELISA试剂盒及其使用方法 |
CN102901815B (zh) * | 2012-11-05 | 2014-10-22 | 武汉远征世纪制药有限公司 | 一种检测TrkB受体816/817位酪氨酸位点活性的ELISA试剂盒及其使用方法 |
US10392438B2 (en) | 2014-05-16 | 2019-08-27 | Pfizer Inc. | Bispecific antibodies |
CN104524568B (zh) * | 2015-01-08 | 2018-04-20 | 中国人民解放军第二军医大学 | 一种治疗肥胖症的药物组合物及其应用 |
BR112018001900A2 (pt) | 2015-07-28 | 2018-09-18 | Otonomy, Inc. | composições agonistas de trkb ou trkc e métodos para o tratamento de condições óticas |
CA3005491A1 (en) | 2015-11-17 | 2017-05-26 | Glaxosmithkline Intellectual Property Development Limited | Binding agonists for treatment of neurological and other disorders |
US9914781B1 (en) | 2016-11-08 | 2018-03-13 | Glaxosmithkline Intellectual Property Development Limited | Binding agonist for treatment of neurological and other disorders |
EP3612625A4 (en) | 2017-04-21 | 2021-08-18 | Mellitus, LLC | PROCEDURE AND ANTIBODIES FOR DIABETES ASSOCIATED APPLICATIONS |
US10793634B2 (en) * | 2017-06-09 | 2020-10-06 | Boehringer Ingelheim International Gmbh | Anti-TrkB antibodies |
WO2019108662A1 (en) * | 2017-11-30 | 2019-06-06 | Regeneron Pharmaceuticals, Inc. | Anti-trkb monoclonal antibodies and methods of use |
JP7411559B2 (ja) * | 2018-02-26 | 2024-01-11 | ミネルバ バイオテクノロジーズ コーポレーション | Anti-muci*抗体を用いた診断法 |
CN110818797B (zh) * | 2018-08-09 | 2022-11-04 | 东莞市朋志生物科技有限公司 | 一种抗人ca153蛋白的重组抗体 |
CN117043186A (zh) | 2020-10-21 | 2023-11-10 | 勃林格殷格翰国际有限公司 | 用于治疗眼部疾病的激动性TrkB结合分子 |
WO2023125485A1 (en) * | 2021-12-28 | 2023-07-06 | 4B Technologies (Beijing) Co., Limited | TrkB ANTIBODY AND APPLICATION THEREOF |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0768377A1 (en) | 1988-09-02 | 1997-04-16 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
CA2108147C (en) | 1991-04-10 | 2009-01-06 | Angray Kang | Heterodimeric receptor libraries using phagemids |
US5885793A (en) | 1991-12-02 | 1999-03-23 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
AU696293B2 (en) | 1993-12-08 | 1998-09-03 | Genzyme Corporation | Process for generating specific antibodies |
AU1736495A (en) | 1994-01-31 | 1995-08-15 | Trustees Of Boston University | Polyclonal antibody libraries |
US5601820A (en) * | 1994-07-07 | 1997-02-11 | Children's Hospital Of Philadelphia | Compositions and methods of making and using human full length TRK-B |
CN101273064A (zh) * | 2005-06-06 | 2008-09-24 | 惠氏公司 | 抗-TrkB单克隆抗体及其用途 |
CA2637707A1 (en) * | 2006-02-02 | 2007-08-09 | Rinat Neuroscience Corporation | Methods for treating obesity by administering a trkb antagonist |
EP1988923A1 (en) * | 2006-02-02 | 2008-11-12 | Rinat Neuroscience Corp. | Methods for treating unwanted weight loss or eating disorders by administering a trkb agonist |
-
2007
- 2007-11-06 AU AU2007316418A patent/AU2007316418A1/en not_active Abandoned
- 2007-11-06 RU RU2009121641/10A patent/RU2009121641A/ru unknown
- 2007-11-06 CA CA002669205A patent/CA2669205A1/en not_active Abandoned
- 2007-11-06 US US12/516,187 patent/US20100150914A1/en not_active Abandoned
- 2007-11-06 EP EP07868672A patent/EP2087007A2/en not_active Withdrawn
- 2007-11-06 MX MX2009004881A patent/MX2009004881A/es not_active Application Discontinuation
- 2007-11-06 JP JP2009536439A patent/JP2010509354A/ja active Pending
- 2007-11-06 EA EA200970469A patent/EA200970469A1/ru unknown
- 2007-11-06 KR KR1020097011751A patent/KR20090088896A/ko not_active Application Discontinuation
- 2007-11-06 WO PCT/US2007/083774 patent/WO2008058127A2/en active Application Filing
- 2007-11-06 BR BRPI0719000-0A patent/BRPI0719000A2/pt not_active IP Right Cessation
- 2007-11-06 CN CNA2007800442715A patent/CN101573381A/zh active Pending
- 2007-11-09 TW TW096142572A patent/TW200829270A/zh unknown
- 2007-11-09 CL CL200703236A patent/CL2007003236A1/es unknown
- 2007-11-09 PE PE2007001546A patent/PE20081168A1/es not_active Application Discontinuation
- 2007-11-09 AR ARP070105005A patent/AR063640A1/es unknown
-
2009
- 2009-04-29 ZA ZA200902943A patent/ZA200902943B/xx unknown
- 2009-04-30 IL IL198468A patent/IL198468A0/en unknown
- 2009-05-07 CR CR10779A patent/CR10779A/es not_active Application Discontinuation
- 2009-05-08 NI NI200900081U patent/NI200900081U/es unknown
- 2009-05-08 TN TNP2009000181A patent/TN2009000181A1/fr unknown
- 2009-05-08 DO DO2009000102A patent/DOP2009000102A/es unknown
- 2009-05-11 CO CO09047482A patent/CO6180432A2/es not_active Application Discontinuation
- 2009-05-27 MA MA31923A patent/MA30922B1/fr unknown
- 2009-05-28 SM SM200900040T patent/SMAP200900040A/it unknown
- 2009-06-08 EC EC2009009392A patent/ECSP099392A/es unknown
- 2009-06-09 NO NO20092217A patent/NO20092217L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NO20092217L (no) | 2009-06-09 |
CA2669205A1 (en) | 2008-05-15 |
BRPI0719000A2 (pt) | 2013-12-10 |
TN2009000181A1 (en) | 2010-10-18 |
SMAP200900040A (it) | 2010-01-19 |
WO2008058127A2 (en) | 2008-05-15 |
WO2008058127A9 (en) | 2008-08-21 |
AR063640A1 (es) | 2009-02-04 |
KR20090088896A (ko) | 2009-08-20 |
ZA200902943B (en) | 2010-05-26 |
NI200900081U (es) | 2010-03-16 |
MX2009004881A (es) | 2009-05-21 |
US20100150914A1 (en) | 2010-06-17 |
JP2010509354A (ja) | 2010-03-25 |
AU2007316418A1 (en) | 2008-05-15 |
DOP2009000102A (es) | 2010-10-31 |
EA200970469A1 (ru) | 2010-04-30 |
IL198468A0 (en) | 2011-08-01 |
CO6180432A2 (es) | 2010-07-19 |
WO2008058127A3 (en) | 2008-10-02 |
MA30922B1 (fr) | 2009-11-02 |
CR10779A (es) | 2009-07-03 |
CN101573381A (zh) | 2009-11-04 |
ECSP099392A (es) | 2009-07-31 |
EP2087007A2 (en) | 2009-08-12 |
CL2007003236A1 (es) | 2008-06-13 |
RU2009121641A (ru) | 2010-12-20 |
TW200829270A (en) | 2008-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20081168A1 (es) | Agonistas de los anticuerpos de la quinasa trkb y sus usos | |
GT200600004A (es) | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentracion sanguinea de glp-1 | |
PE20090762A1 (es) | Compuestos organicos | |
CL2008003116A1 (es) | Compuestos heterocíclicos bicíclicos; composición farmacéutica que comprende a dichos compuestos; y su uso en el tratamiento o prevención de enfermedades tales como diabetes, obesidad, trastorno metabólico, enfermedad cardiovascular entre otras. | |
CL2012001337A1 (es) | Uso de una combinacion farmacéutica que comprende un inhibidor de dpp-4 y opcionalmente un segundo y/o un tercer agente diabético seleccionado entre biguanidas, tiazolidindionas, sulfonilureas, glinidas, inhibidores de alfa-glucosidasa, glp-1 e insulina, diferentes entre ellos, para el tratamiento de diabetes mellitus de tipo 2. | |
CL2007002492A1 (es) | Compuestos derivados de bi-,tri o policiclos no aromaticos, inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo i; proceso de preparacion de estos; composicion famaceutica que los comprende; uso en el tratamiento de enfermedades tales como la obesidad, diabetes y dislipidemia, entre otras. | |
CL2007001915A1 (es) | Compuesto cristalino de 6-[4-cloro-3-(4-etoxibencil)fenil]tetrahidropiran-2,3,4,5,-tetraol; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y su uso para preparar un medicamento para tratar diabetes, dislipidemia, obesidad, entre otras. | |
PE20110771A1 (es) | Anticuerpos monoclonales contra el inhibidor de la via del factor tisular (tfpi) | |
UY29020A1 (es) | Saliciltiazoles sustituidos con difenilamina o derivados de difenilamina, procedimientos para su preparacinn y su uso.- | |
DOP2009000283A (es) | Compuestos moduladores de sirtuina | |
ECSP11011277A (es) | Composición farmacéutica que comprende un inhibidor de sglt2, un inhibidor de dpp-iv y, opcionalmente, un agente antidiabético adicional, y sus usos. | |
CR9351A (es) | Composiciones y metodos para aplicaicon topica y suministro transdermico de toxina botulinica | |
ECSP13012661A (es) | Composición farmacéutica, métodos de tratamiento y usos de la misma. | |
BRPI0517701A8 (pt) | métodos de tratamento de diabetes mellitus | |
GT200600426A (es) | Formulacion novedosa | |
AR109263A2 (es) | Composición que comprende moxidectina | |
UY33700A (es) | ?combinaciones farmacéuticas para el tratamiento de trastornos metabólicos?. | |
CL2008002424A1 (es) | Composicion farmaceutica que comprende un compuesto derivado de pirazol-o-glucosido; y uso de la composicion farmaceutica para el tratamiento de la diabetes mellitus, tolerancia anormal a la glucosa e hiperglucemia, trastornos metabolicos, entre otras. | |
DOP2009000269A (es) | Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos | |
CL2008003582A1 (es) | Uso de una composicion farmaceutica que contiene cisteamina o cistamina en la preparacion de un medicamento util para el tratamiento de una enfermedad de higado graso no alcholico (nafld) o esteatohepatitis no alcoholica (nash). | |
CL2007001749A1 (es) | Compuesto derivado de 2-arilamino-4-(heterociclo)aminopirimidina, inhibidores de la proteina quinasa c-alfa; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de diabetes, cancer, enfermedad cardiaca coronaria, aterosclerosis, entre otras. | |
AR054909A1 (es) | Modulacion de los receptores activados por el proliferador de peroxisomas | |
CL2011002182A1 (es) | Compuestos heterociclicos que contienen 2 o mas heterociclos con n como heteroatomos del ciclo, agonistas de gpr119 e inhibidores de dpp-iv; composicion farmaceutica; y su uso en el tratamiento de la diabetes tipo ii, obesidad, sindrome metabolico, tolerancia deteriorada a la glucosa e hiperlipidemia, entre otras enfermedades.. | |
AR065145A1 (es) | Metodo para reducir la inflamacion y el estres en mamiferos | |
CL2011000147A1 (es) | Compuestos derivados de carbamato de alquiltiazol, inhibidores de la enzima faah; composicion farmaceutica que los comprende; procedimiento de preparacion de estos; y sus usos en el tratamiento de dolores agudos o cronicos, vertigo, vomitos, nauseas, epilepsias, entre otras. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |